# ASC2ESCALATE (NCT05384587)

> Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05384587
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Chronic Myelogenous Leukemia - Chronic Phase
- Interventions: asciminib
- Enrollment: 34
- Primary outcome: Percentage of participants who achieve Major Molecular Response (MMR) in the 2L setting

## Commentary we found

- YouTube: 10
- Podcasts: 2
- X threads: 1
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=asc2escalate-nct05384587

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05384587", "email": "<work email>"}; the inbox owner confirms by the emailed link.